The Challenge of Treating Malattia Leventinese

Malattia Leventinese (ML), also referred to clinically as Doyne honeycomb retinal dystrophy, is a progressive inherited retinal disease that currently has no approved disease-modifying treatments. For decades, management has been strictly observational, focusing on supportive care and monitoring for severe complications such as choroidal neovascularization, which can be treated with anti-VEGF injections if it occurs. However, these interventions do not address the underlying cause of the progressive vision loss. The disease is caused by a specific, well-characterized mutation (Arg345Trp) in the EFEMP1 gene, which leads to the toxic accumulation of the mutant fibulin-3 protein beneath the retina, forming drusen and eventually causing the death of retinal cells.

Because the disease results from a "toxic gain-of-function"—meaning the mutant protein actively causes harm to the cellular environment rather than simply failing to perform its normal physiological job—traditional gene replacement therapies are not effective. In a loss-of-function disease, adding a healthy copy of the gene can restore function. But in ML, the presence of the mutant protein is the problem. Therefore, a successful treatment must reduce or eliminate the mutant protein without completely removing the healthy version of the protein, if possible, to maintain normal cellular function.

Enter Antisense Oligonucleotides (ASOs)

One of the most promising and innovative avenues of research for Malattia Leventinese involves the use of antisense oligonucleotides (ASOs). ASOs are short, synthetic strands of DNA or RNA that are precisely designed to bind to specific messenger RNA (mRNA) molecules within the cell. mRNA is the intermediary molecule that carries the genetic instructions from the DNA in the nucleus to the cellular machinery that builds proteins. By binding to the target mRNA, ASOs can prevent this machinery from translating the mRNA into a protein, effectively "silencing" the gene and halting the production of the harmful protein.

Allele-Specific Targeting

Recent preclinical research has focused heavily on developing allele-specific ASOs for ML. Because patients with ML typically have one mutated copy of the EFEMP1 gene (the allele carrying the Arg345Trp mutation) and one normal, healthy copy, the goal is to design an ASO that specifically recognizes and binds only to the mutated EFEMP1 mRNA. This precision targeting aims to silence the production of the toxic mutant fibulin-3 protein while leaving the normal EFEMP1 mRNA intact, allowing the cell to continue producing the healthy fibulin-3 protein necessary for maintaining the extracellular matrix.

In sophisticated laboratory models using patient-derived retinal pigment epithelium (RPE) cells—created by reprogramming patient cells into induced pluripotent stem cells and then differentiating them into retinal cells—researchers have demonstrated that these targeted ASOs can successfully and specifically reduce the expression of the mutant EFEMP1 transcript.

Reversing the Disease Phenotype

The results from these early in vitro studies are highly encouraging and represent a significant leap forward in ML research. By effectively knocking down the mutant protein, the ASO treatment was able to resolve several key pathological changes associated with the disease. In the patient-derived cell models, treatment led to:

  • Reduction in Extracellular Matrix Accumulation: The abnormal buildup of proteins like TIMP3 and other matrix components was significantly reduced, restoring a more normal basement membrane architecture.
  • Decreased Lipid Deposition: The abnormal accumulation of lipids, a primary component of drusen, was markedly diminished.
  • Restoration of Cellular Structure: The RPE cells regained a more normal, healthy structure and function, indicating that the toxic environment was being cleared.

Importantly, these improvements were observed even after the disease phenotype had already begun to develop in the cell models. This suggests that ASO therapy could potentially not only halt the progression of drusen formation but might also allow the eye to clear existing deposits and reverse some of the damage.

Looking Ahead

While ASO therapy for Malattia Leventinese is still in the preclinical stages of research, it represents a highly targeted, logical, and promising approach to treating the root cause of the disease. The ability to specifically silence a toxic gene without affecting its healthy counterpart is a powerful tool in modern genetics. Further studies will be needed to optimize the delivery of ASOs to the retina—likely requiring specialized injection techniques—and to ensure their long-term safety and efficacy in animal models before they can advance to human clinical trials. Nevertheless, the progress made thus far offers genuine hope for a future where ML can be effectively treated.

*

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.